Cipla Ltd v. Novartis Ag

Court

District Court, D. New Jersey (D.N.J.)
Official Court Website →

Assigned judge

Stanley R. Chesler · 3,374 cases in index

Docket number

2:19-cv-20810

Cause

35:271 Patent Infringement
35 U.S.C. § 271 — Patent infringement

Nature of suit

835 Patent - Abbreviated New Drug Application(ANDA)
Hatch-Waxman patent disputes over a generic-drug (ANDA) application.

Jurisdiction

Federal Question

Jury demand

None

Date filed

11/26/2019

Date terminated

02/05/2020

623 Patent - ANDA cases in this court are indexed here.

Parties

• plaintiff · Cipla Ltd · 25 cases
• defendant · Novartis Ag Pharmaceuticals & Biotechnology · 176 cases

About Patent - ANDA Lawsuits

ANDA patent cases arise when a generic-drug maker files an Abbreviated New Drug Application and the brand-name patent holder sues for infringement under the Hatch-Waxman Act.

Frequently Asked Questions

What is Cipla Ltd v. Novartis Ag?

Cipla Ltd v. Novartis Ag is a federal patent - anda lawsuit filed on 11/26/2019 in the District Court, D. New Jersey. The case was terminated on 02/05/2020. ANDA patent cases arise when a generic-drug maker files an Abbreviated New Drug Application and the brand-name patent holder sues for infringement under the Hatch-Waxman Act.

What type of case is this?

It is classified as “Patent - ANDA” under the federal nature-of-suit system. ANDA patent cases arise when a generic-drug maker files an Abbreviated New Drug Application and the brand-name patent holder sues for infringement under the Hatch-Waxman Act.

What court is the case in?

The case is in the District Court, D. New Jersey, docket number 2:19-cv-20810.

When was the case filed?

Cipla Ltd v. Novartis Ag was filed on 11/26/2019. It was terminated on 02/05/2020.

What law is the case brought under?

The docket lists the cause as 35 U.S.C. § 271 — Patent infringement.